rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

ProKidney Corp. - Class A

PROK · Nasdaq

Health CareBiotechnologyNot moving yet

PROK stood above a rising 150-day average in 8 of the last 52 weekly readings, and has been out of that trend for the last 43 weeks. It is 20.2% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 43
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$4.0M
Officials’ trades on record
0
Institutions holding
68 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 8 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.0M$0$1.4MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months5
Buyers · sellers0 · 1
WhoDidSharesTraded
Brian Jg PereiraDirectorsold222,948at $1.4220 Aug 2026filed 20 Aug 2026
Brian Jg PereiraDirectorsold27,052at $1.4220 Aug 2026filed 20 Aug 2026
Brian Jg PereiraDirectorsold222,949at $1.4419 Aug 2026filed 20 Aug 2026
Brian Jg PereiraDirectorsold27,051at $1.4419 Aug 2026filed 20 Aug 2026
Brian Jg PereiraDirectorsold229,338at $1.3718 Aug 2026filed 20 Aug 2026
Brian Jg PereiraDirectorsold27,826at $1.3718 Aug 2026filed 20 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders68+3 on the quarter
New · exited23 · 21
Reported value$98.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
MONTANOVA CAPITAL, LLCunchanged · filed 14 Aug 202612,341,266$25.2M00.0%
MORGAN STANLEYadded · filed 13 Aug 20269,854,178$20.1M+898,211+10.0%
BlackRock, Inc.added · filed 7 Aug 20265,197,227$10.6M+3,810,111+274.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20262,390,147$4.9M+1,159,738+94.3%
Bleichroeder LPunchanged · filed 13 Aug 20262,000,000$4.1M00.0%
Hennion & Walsh Asset Management, Inc.added · filed 8 Jul 20261,847,749$3.8M+236,056+14.6%
Artia Global Partners LPunchanged · filed 14 Aug 20261,806,939$3.7M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,175,257$2.4M+28,320+2.5%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20261,099,400$2.2M-151,394−12.1%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 20261,054,705$2.2M-1,216,872−53.6%
30 Jun 2025 – 30 Jun 2026
83766Jun 25Sep 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Brian J.G. Pereira Company insiderDirector · last 20 Aug 20260 · 5
Kenneth Thomas Locke Company insiderChief Technical Officer · last 1 Jul 20260 · 0
Todd C. Girolamo Company insiderChief Legal Officer · last 12 Jun 20260 · 0
Alan Lotvin Company insiderDirector · last 28 May 20260 · 0
Jennifer A. Fox Company insiderDirector · last 28 May 20260 · 0
Pablo G. Legorreta Company insiderDirector, 10% owner · last 28 May 20261 · 0
Santos Jose Ignacio Jimenez Company insiderDirector · last 28 May 20260 · 0
Uma Sinha Company insiderDirector · last 28 May 20260 · 0
William F. Doyle Company insiderDirector · last 28 May 20260 · 0
Control Empresarial de Capitales S.A. de C.V. Company insider10% owner, Other · last 28 Apr 202613 · 0
Bruce Culleton Company insiderChief Executive Officer · last 1 Mar 20260 · 0
Darin J. Weber Company insiderChief Regulatory Officer · last 1 Mar 20260 · 10

Same industry

MRNA ModernaLeading+154%
IOVA Iovance BiotherapeuticsLeading+133%
ABCL AbCellera BiologicsLeading+61%
ENTX Entera BioLeading+49%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+46%
HELP Helus PharmaLeading+37%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-54.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$108.5M
Free cash flowFY 2025 · to 31 Dec 2025−$135.3M

Analyst forecasts

No analyst forecasts yet.